|
Mr. Chappell has served as a member of the Board of Directors of Salix since December 1993 and as a member of its Audit and Compensation Committees since December 1994. He was named Chairman of the Board in September 2003. In 1990 he founded Plexus Ventures, which specializes in business development and strategic transactions for clients in the biotechnology, pharmaceutical and drug delivery industries. Prior to founding Plexus, Mr. Chappell served as Chairman, Worldwide Pharmaceuticals for SmithKline Beecham plc (now GlaxoSmithKline plc), where he was responsible for the multi-billion dollar ethical pharmaceutical business with 30,000 employees worldwide. During his 28 years at SmithKline Beecham, Mr. Chappell also headed the International Consumer Products (OTC) operations and the Corporate Development Center. He has served as a Director of SmithKline Beecham, the Pharmaceutical Manufacturers Association (now PhRMA) and the Industrial Biotechnology Association (now BIO). Additionally, Mr. Chappell has served as a Director of a number of biotechnology companies and is currently a member of Main Line Health Board of Governors. Mr. Chappell holds a B.A. degree from Harvard University and attended the Wharton School of the University of Pennsylvania. | 